

QMENTA[®]

INVEST IN THE CONQUEST OF THE BRAIN


capitalcell.es/campaign/qmenta

Funding round: **1.350.000€**

**QMENTA offers a 20% discount
for investments made before
November 18th.**

QMENTA provides an AI cloud platform and state-of-the-art biomarkers to aggregate, standardize, and analyze medical imaging and related data.

By using one system for upload, reading, and quantification of images, the platform helps to efficiently run imaging trials with **reductions in time, costs, and risks**. Applying AI tools on the imaging data allows the provision of accurate and quantitative measures that help the medical professionals make better treatment decisions for their patients.



INVESTMENT OPPORTUNITY

Estimated return

x12



Estimated exit

2021-2025



Minimum investment: 500€

Type of expected exit: IPO or company sale

Syndicated investment

Drag-along

Tag-along

Rights to join board meetings

Information to shareholders every 3 months

UNIQUE SELLING POINTS

- Current 2019 sales above 1.6M€ , a +318% increase year-to-year growth
- Portfolio of international investors experts in Health IT as Walter Gilbert, Chris Llewellyn, Chris Klaus and Mike del Prado
- Technology validated by 37 scientific publications and 7 algorithms patents
- A unique dataset of over 6 million high quality brain scans valued at over 36M€
- Compliant with worldwide standards including FDA title 21 part 11& 820, HIPPA, GDPR, IEC 62304, and ISO13485 certification for the secure management of medical data.
- Client base includes 4 pharma, 24 hospitals and universities, 2 foundations, 2 European-wide consortiums, and direct relationships with more than 1000 Key Opinion Leaders in neurology

WHY CAPITALCELL INVESTS IN QMENTA?

QMENTA has three factors in its favour:

- 1) The company is based on a powerful technology and whose development has been supervised and supported by the scientific advice of one of the best neurologists in the world, Pablo Villoslada. Proof of this is that they are managing to develop applications to both treat patients (clinical) and to improve the development of new drugs (R&D); In this field, QMENTA's technology can facilitate that in the near future there are cures for brain diseases so far incurable.
- 2) One of the fastest growing markets in the world. The medical sector is now ready for solutions based on Artificial Intelligence, and the use of AI in the analysis of medical images is growing a spectacular 40% annually. It is estimated that by 2024 the Medical Imaging market will reach \$ 2.4 billion.
- 3) An ambitious management team with a huge commercial capacity in international markets. Despite being a startup "made in Barcelona", the founding team is international and has demonstrated an enormous capacity to raise capital and to obtain contracts worldwide, particularly in the USA market.

For these and other reasons, we believe that QMENTA is a company with a growth potential above the average, and that it is in a phase of commercial and technological maturity that makes an investment justifiable.

MAIN RISKS

The main challenges of QMENTA are in the capacity for rapid growth and in the absence of more complete solutions that can make them competitive.


At this time, the capacity for growth of the project is to be able to obtain more funding and thus be able to go faster, so it will be critical that they manage to raise their next round in good conditions. Until now the company has always been able to get investment both in Spain and in the rest of the world (particularly in the United States), and we hope that the next round can also be raised in good conditions.

On the other hand, the space of AI applied to medical imaging is growing rapidly and will soon be attractive to the leaders of the medical and/or computer sector (Google, Amazon ...), and the speed with which QMENTA manages to grow will be key to determine if in the future they will be replaced by those giants or rather acquired by hundreds of millions.

QMENTA®

INVEST IN THE CONQUEST OF THE BRAIN

capitalcell.es/campaign/qmenta



QMENTA is a company in Barcelona founded in 2013. Currently, QMENTA operates with a team of 29 experts in neuroimaging, image processing, artificial intelligence, and software engineering, but it is also a company that is **already invoicing almost 1M euros per year** and has experts in licensing and business development internationally.

How QMENTA amends the issues in the fragmented medical imaging space

QMENTA has a unique system of Artificial Intelligence housed in the cloud that allows **quantifying brain images** anywhere and at any time.

The software provides ample ability to analyze multiple parts of the brain and manage all related data. The goal is to **help doctors read and interpret** in a simpler way the very valuable information that is obtained from scanners, TACs and other imaging systems, in order to offer a better treatment to their patients and to optimize the clinical trials. That is why all the studies carried out through the QMENTA platform **have been more profitable, faster and have produced better results.**

The platform complies with the highest standards of the industry, both in the European Union and in the United States, and has patented seven algorithms that have achieved:

Helping understand the brain and the evolution of brain diseases in a non-invasive way,

Offering objective and quantitative measurements of the tissue properties inside the brain that can evaluate the efficacy of the drug,

Providing **better patient characterization** by dividing the patients into sub-categories depending on how and where the brain damage is present.

Our clients report 60-75% decrease in costs by running their studies through QMENTA platform.

WHAT THE EXPERTS SAY

Alexei Levitchi Senior researcher in molecular biology, bioinformatics and statistics.

"I think the project is mature enough to expand its market: the accumulated experience, the demonstrated ability to get customers, the equipment and the infrastructure available to it."

Andrea Fernández Postdoctoral researcher at the Hospital Clínic de Barcelona, expert in cellular and molecular biology and clinical trials to improve and develop diagnostic and prognostic methods for patients.

"The idea is brilliant and attacks one of the current issues in the field of medicine: the management of large amounts of information and its maximum use."

Kit Vaughan Expert in Medical and Biological Engineering, in medical devices and CEO of a company with a system of early detection of breast cancer.

"To judge by the qualifications of both the executive team and its advisors, it is an extremely well qualified team."


Dr. Maureen Ajuebor Consultant specialized in preclinical, clinical and epidemiology phases. Expert in liver immunology and investment in this sector.

"It is a first-class company with a very timely, unique and innovative approach to diagnosis through neuroimaging that should transform future diagnosis, clinical trials and data analysis in brain pathology."

Magí Andorrà Biomedical researcher specialized in neuroimaging of multiple sclerosis, Hospital Clínic de Barcelona.

"QMENTA was one of the first players in the market and its product [...] makes it a more complete company than its competitors, offering only one or the other of these characteristics. Its innovation is an all-in-one solution for neuroimaging studies."

INVEST IN
**THE CONQUEST
OF THE BRAIN**
QMENTA[®]



*Capital Cell team will help you
to complete your investment.*

*Do you have any
question?*

INVEST

REQUEST A MEETING